-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $33

Benzinga·02/10/2026 11:47:49
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $26 to $33.